
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
Professor Frank Behrens is Professor of Translational Rheumatology, Immunology and Inflammation Medicine and Head of the Inflammation Clinic, University Hospital, Frankfurt am Main, Germany, and Deputy Director, Fraunhofer Institute for Translational Medicine & Pharmacology (ITMP), Goethe University, Frankfurt am Main. He is also a member of the board of directors of the Fraunhofer Cluster of Excellence for Immune-Mediated Disease (CIMD).
Professor Behrens studied biology at the Johannes Gutenberg University in Mainz, Germany, before going on to study human medicine. He completed his doctorate in haematology and oncology before training in internal medicine and rheumatology.
Professor Behrens' main research interest is the pathophysiological understanding of spondyloarthritis, rheumatoid arthritis and mixed connected tissue disease. The focus is on understanding the links between these rheumatic conditions and associated skin and bowel diseases. The aim of the work is to develop new drug therapies and implement personalised treatment approaches using combined biomarker analyses and new imaging techniques. Since 2001, he has gained experience in clinical research and development as Principal Investigator, Chief Investigator and Managing Investigator. He is responsible for several investigator-initiated studies in rheumatic diseases.
Professor Behrens has published numerous articles in peer-reviewed journals and is author of several textbooks in the field of rheumatic diseases.
Professor Behrens is a member of various international committees and study groups such as the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the Expert Panel Measures in Pulmonary Arterial Hypertension Related to Outcome of Systemic Sclerosis (EPOSS) and the Psoriatic Arthritis Genetic European Consortium (PAGE).
Achieving ACR50 is associated with improvements in quality of life for patients with PsA.1 Dive into the data supporting higher treatment targets in clinical...
Watch Prof Lars Erik Kristensen and Prof Frank Behrens discuss how MDA is a realistic treatment target in clinical practice and the barriers to achieving it for...
Treatment for PsA should target a broad range of musculoskeletal and extra-articular manifestations.1 Listen to Assoc. Prof Philipp Sewerin explain how MDA can...
Explore the key conclusions around aiming for higher treatment targets, discussed at the UCB-sponsored Satellite Symposium presented at EULAR 2023.
axSpA is a complex disease with a significant burden on many aspects of daily life.1,2 Dive into the importance of ASAS40 for your patients with Dr Fabian Proft.
Watch Prof Robert Landewé discuss the importance of using ASDAS <2.1 as a treatment target for patients with axSpA.